Regulatory
It's a pattern we're starting to see: a manufacturer hears that the EU and Switzerland signed a new recognition agreement for medical devices, and assumes the Swiss-specific compliance work — a CH-REP, separate Swissmedic registration — is no longer necessary. That assumption is premature, and acting on it now creates real regulatory risk.
What actually happened
On March 2, 2026, the EU and Switzerland signed an updated Mutual Recognition Agreement (MRA) that will, once it enters into force, restore mutual recognition for medical devices between the two markets. Since the previous MRA lapsed in 2021, Switzerland has been treated as a third country under the EU's Medical Device Regulation — which is exactly why manufacturers now register under Switzerland's own framework, the Medical Device Ordinance (MedDO) and, for in vitro diagnostics, the IvDO, and why a CH-REP and a separate Swiss registration track (including a CHRN) became necessary in the first place. This agreement is the mechanism that eventually unwinds that.
What hasn't changed — and won't for a while
Signing an agreement is not the same as it taking effect. Ratification still has to clear the Swiss Parliament, and a public referendum is a realistic possibility given how Swiss-EU treaties are typically handled. Industry estimates put full mutual recognition no earlier than 2028, assuming ratification goes smoothly. Until then, every current obligation stands: CH-REP remains mandatory, Swissmedic registration remains mandatory, and Swiss-specific labeling and documentation requirements are unchanged. If you're currently working with a CH-REP, nothing about that arrangement needs to change today.
A second deadline that already came and went
While the MRA gets the attention, a separate and already-active requirement is easy to miss: as of July 1, 2026, registration in swissdamed, Switzerland's national medical device database, became mandatory. This obligation is entirely independent of the MRA and stays in effect regardless of how or when the agreement is ratified. For manufacturers deciding what to prioritize, swissdamed is the nearer, unavoidable item — not something to defer while waiting on the MRA.
What this means for your planning
- Don't dismantle your CH-REP structure in anticipation of the MRA — it's a future-state simplification, not a current exemption.
- Treat swissdamed registration as a near-term compliance item, separate from any MRA-related planning.
- Build MRA awareness into your longer-term roadmap, not the one you're executing this year or next.
This is precisely the kind of regulatory timing question a Market Validation engagement is designed to clarify — separating what's required of you today from what might simplify things tomorrow, so your Swiss commercial infrastructure gets built on the rules that actually apply right now.